A computer-implemented method for predicting the efficacy of midostaurin for treatment of acute myeloid leukaemia in an individual patient, comprising the steps of: (a) (i) analysing data relating to the expression on the surface of the patient's leukaemia cells of a group of CD markers consisting of CD11b, CD14, CD15, CD 16, CD33, CD38, CD44, CD45, CD64, CD 123 and HLA-DR to determine whether said group of CD markers is expressed at a high level on the surface of the patient's leukaemia cells; and (ii) analysing data relating to phosphorylation in the leukaemia cells at one or more phosphorylation sites selected from: GSK3A at pS21; PRKCD at Y313, pT507, pT295, pT218, and/or pS664 of PRKCD; STK10 at pS20 and/or pS13 of STK10; PAK1 at pS144 ofPAK1; PAK2 at pS141 ofPAK2; MAPK1 at Y187 and/or T185; and MAPK3 at T202 and/or Y204 to determine whether one or more of said phosphorylation sites is phosphorylated or is phosphorylated at a high level in the patient's leukaemia cells; and (b) where said group of CD markers is expressed at a high level on the surface of the patient's leukaemia cells, and one or more of said phosphorylation sites in the leukaemia cells is phosphorylated or is phosphorylated at a high level, predicting that the acute myeloid leukaemia in the patient may be effectively treated with midostaurin (a) (i) analysing data relating to the expression on the surface of the patient's leukaemia cells of a group of CD markers consisting of CD11b, CD14, CD15, CD 16, CD33, CD38, CD44, CD45, CD64, CD 123 and HLA-DR to determine whether said group of CD markers is expressed at a high level on the surface of the patient's leukaemia cells; and (ii) analysing data relating to phosphorylation in the leukaemia cells at one or more phosphorylation sites selected from: GSK3A at pS21; PRKCD at Y313, pT507, pT295, pT218, and/or pS664 of PRKCD; STK10 at pS20 and/or pS13 of STK10; PAK1 at pS144 ofPAK1; PAK2 at pS141 ofPAK2; MAPK1 at Y187 and/or T185; and MAPK3 at T202 and/or Y204 to determine whether one or more of said phosphorylation sites is phosphorylated or is phosphorylated at a high level in the patient's leukaemia cells; and (i) analysing data relating to the expression on the surface of the patient's leukaemia cells of a group of CD markers consisting of CD11b, CD14, CD15, CD 16, CD33, CD38, CD44, CD45, CD64, CD 123 and HLA-DR to determine whether said group of CD markers is expressed at a high level on the surface of the patient's leukaemia cells; and (ii) analysing data relating to phosphorylation in the leukaemia cells at one or more phosphorylation sites selected from: GSK3A at pS21; PRKCD at Y313, pT507, pT295, pT218, and/or pS664 of PRKCD; STK10 at pS20 and/or pS13 of STK10; PAK1 at pS144 ofPAK1; PAK2 at pS141 ofPAK2; MAPK1 at Y187 and/or T185; and MAPK3 at T202 and/or Y204 to determine whether one or more of said phosphorylation sites is phosphorylated or is phosphorylated at a high level in the patient's leukaemia cells; and (b) where said group of CD markers is expressed at a high level on the surface of the patient's leukaemia cells, and one or more of said phosphorylation sites in the leukaemia cells is phosphorylated or is phosphorylated at a high level, predicting that the acute myeloid leukaemia in the patient may be effectively treated with midostaurin